CVS Caremark: Gilead must lower price of new HIV drug to get on formularies

Taking stock of the drug industry, from the lab to the medicine chest

October 22, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

PATRICK T. FALLON/AFP via Getty Images STAT+ | CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies Gilead says it is still in "active" discussions with payers and expects 75% access for Yeztugo by December By Ed Silverman STAT+ | Companies tout a novel payment model for obesity drugs, other medications in drive to lower costs Startups are offering employers a way to lower insurance costs by not covering pricey medications, but subsidizing drugs like Wegovy when paid in cash. By Elaine Chen STAT+ | The cost of health insurance for a family jumps to $27,000 KFF survey finds premiums grew 6% in 2025, compared to general inflation of 2.7% and wage growth of 4%. Health insurance for a family is now $27,000 a year. By Tara Bannow

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser